RGNX vs. ALEC, CCCC, QURE, BDTX, CGEN, ACLX, ADMA, APGE, IOVA, and VCEL
Should you be buying REGENXBIO stock or one of its competitors? The main competitors of REGENXBIO include Alector (ALEC), C4 Therapeutics (CCCC), uniQure (QURE), Black Diamond Therapeutics (BDTX), Compugen (CGEN), Arcellx (ACLX), ADMA Biologics (ADMA), Apogee Therapeutics (APGE), Iovance Biotherapeutics (IOVA), and Vericel (VCEL). These companies are all part of the "medical" sector.
REGENXBIO (NASDAQ:RGNX) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, earnings, profitability, institutional ownership, media sentiment, valuation and risk.
REGENXBIO has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Comparatively, Alector has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.
In the previous week, Alector had 6 more articles in the media than REGENXBIO. MarketBeat recorded 10 mentions for Alector and 4 mentions for REGENXBIO. Alector's average media sentiment score of 0.41 beat REGENXBIO's score of 0.00 indicating that Alector is being referred to more favorably in the news media.
REGENXBIO received 279 more outperform votes than Alector when rated by MarketBeat users. Likewise, 65.79% of users gave REGENXBIO an outperform vote while only 60.58% of users gave Alector an outperform vote.
REGENXBIO presently has a consensus target price of $38.58, indicating a potential upside of 174.03%. Alector has a consensus target price of $14.00, indicating a potential upside of 221.10%. Given Alector's higher possible upside, analysts clearly believe Alector is more favorable than REGENXBIO.
Alector has higher revenue and earnings than REGENXBIO. Alector is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.
Alector has a net margin of -125.11% compared to REGENXBIO's net margin of -299.96%. REGENXBIO's return on equity of -70.72% beat Alector's return on equity.
88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 13.1% of REGENXBIO shares are held by company insiders. Comparatively, 9.1% of Alector shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
REGENXBIO beats Alector on 10 of the 18 factors compared between the two stocks.
Get REGENXBIO News Delivered to You Automatically
Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
REGENXBIO Competitors List
Related Companies and Tools
